A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2

Oncotarget
Andrew R LavikClark W Distelhorst

Abstract

Bcl-2 inhibits apoptosis by two distinct mechanisms but only one is targeted to treat Bcl-2-positive malignancies. In this mechanism, the BH1-3 domains of Bcl-2 form a hydrophobic pocket, binding and inhibiting pro-apoptotic proteins, including Bim. In the other mechanism, the BH4 domain mediates interaction of Bcl-2 with inositol 1,4, 5-trisphosphate receptors (IP3Rs), inhibiting pro-apoptotic Ca2+ signals. The current anti-Bcl-2 agents, ABT-263 (Navitoclax) and ABT-199 (Venetoclax), induce apoptosis by displacing pro-apoptotic proteins from the hydrophobic pocket, but do not inhibit Bcl-2-IP3R interaction. Therefore, to target this interaction we developed BIRD-2 (Bcl-2 IP3 Receptor Disruptor-2), a decoy peptide that binds to the BH4 domain, blocking Bcl-2-IP3R interaction and thus inducing Ca2+-mediated apoptosis in chronic lymphocytic leukemia, multiple myeloma, and follicular lymphoma cells, including cells resistant to ABT-263, ABT-199, or the Bruton's tyrosine kinase inhibitor Ibrutinib. Moreover, combining BIRD-2 with ABT-263 or ABT-199 enhances apoptosis induction compared to single agent treatment. Overall, these findings provide strong rationale for developing novel therapeutic agents that mimic the action of BIRD-2 ...Continue Reading

References

Oct 1, 1993·Cancer Genetics and Cytogenetics·R M MohammadA al-Katib
Feb 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kirsten Canté-BarrettGerald R Crabtree
Jan 4, 2007·The Journal of Clinical Investigation·Victoria Del Gaizo MooreAnthony Letai
Jan 27, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Suzanne TrudelXiao-Yan Wen
Jun 23, 2007·Nature Reviews. Cancer·Gregory R MonteithSarah J Roberts-Thomson
Dec 22, 2007·Nature Reviews. Molecular Cell Biology·Richard J Youle, Andreas Strasser
Jan 19, 2008·Nature Reviews. Cancer·Anthony G Letai
Apr 25, 2008·Nature Reviews. Cancer·H Llewelyn Roderick, Simon J Cook
May 3, 2008·Cancer Research·Christin TseSteven W Elmore
Oct 29, 2008·Oncogene·K W Yip, J C Reed
Aug 27, 2009·Proceedings of the National Academy of Sciences of the United States of America·Yi-Ping RongClark W Distelhorst
Feb 18, 2010·Molecular Cell·Jerry E ChipukDouglas R Green
Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Lee A HonigbergJoseph J Buggy
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Jul 23, 2011·Nature Reviews. Cancer·Natalia PrevarskayaYaroslav Shuba
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ranjana H AdvaniNathan H Fowler
Feb 16, 2013·Cancer Cell·Matthew S Davids, Anthony Letai
Jan 8, 2014·Proceedings of the National Academy of Sciences of the United States of America·Ming-Jin ChangClark W Distelhorst
Jan 28, 2014·Drugs·Fiona Cameron, Mark Sanford
Mar 1, 2014·Leukemia·W Hiddemann, B D Cheson
Apr 29, 2014·Biochimica Et Biophysica Acta·Haidar AklGeert Bultynck
May 30, 2014·The New England Journal of Medicine·Richard R FurmanY Lynn Wang
May 30, 2014·The New England Journal of Medicine·Jennifer A WoyachJohn C Byrd

❮ Previous
Next ❯

Citations

Nov 4, 2015·Aging·Tamara VervloessemGeert Bultynck
Feb 1, 2017·Leukemia & Lymphoma·Prithviraj BoseMarina Konopleva
Jan 1, 2020·International Journal of Molecular Sciences·Lucile NoyerDimitra Gkika
Apr 8, 2016·The Journal of Biological Chemistry·Jacqualyn J SchulmanRichard J H Wojcikiewicz
Apr 7, 2016·Oncotarget·Jiusheng DengXingming Deng
Sep 11, 2019·Cold Spring Harbor Perspectives in Biology·Hristina IvanovaGeert Bultynck
Dec 26, 2015·International Journal of Molecular Sciences·Hongrui GuoBangyuan Wu
May 22, 2019·Cold Spring Harbor Perspectives in Biology·Clark W Distelhorst, Martin D Bootman
Feb 17, 2017·Carcinogenesis·Chiara GabelliniDonatella Del Bufalo
Jun 15, 2018·Cell Death and Differentiation·Mart BittremieuxGeert Bultynck
Feb 8, 2021·Biochimica Et Biophysica Acta. Molecular Cell Research·Ian de RidderGeert Bultynck
May 1, 2021·International Journal of Molecular Sciences·Jordan L MorrisNikolay Popgeorgiev
Oct 21, 2021·The FEBS Journal·Robert E Means, Samuel G Katz

❮ Previous
Next ❯

Datasets Mentioned

BETA
ABT-199

Methods Mentioned

BETA
xenograft
Fluorescence
xenografts

Software Mentioned

GenScript
MetaMorph
TAT

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.